Lexicon Pharmaceuticals LXRX Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — revenue?
- Lexicon Pharmaceuticals (LXRX) reported business segments — revenue of $21.1M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — revenue changed year-over-year?
- Lexicon Pharmaceuticals's business segments — revenue increased by 1572.1% year-over-year, from $1.26M to $21.1M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — revenue?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — revenue has grown at a 610.3% compound annual growth rate (CAGR), from $139K to $49.8M.
- What does business segments — revenue mean?
- The total gross income generated by a specific business segment through its primary commercial activities, such as product sales or service delivery. This metric serves as the top-line indicator of market demand and commercial success for the segment's offerings. It provides a baseline for evaluating the segment's contribution to the overall enterprise revenue.